In November 2020, MPP and ViiV Healthcare signed a new voluntary licensing agreement to enable greater access for dolutegravir (DTG) based regimens in certain upper-middle-income countries (UMICs). This new licensing agreement includes Azerbaijan, Belarus, Kazakhstan and Malaysia. Recognising the specific challenges faced by these countries and in response to feedback from the HIV community and the governments, ViiV Healthcare and MPP developed this first-of-its-kind agreement to enable increased access and affordability to generic DTG-based HIV treatment regimens, while also supporting continued investment in much needed innovation.

Country List
Azerbaijan, Belarus, Kazakhstan, Malaysia

GENERIC PARTNERS AND PRODUCT DEVELOPERS